Development of Clinical and Biological Database on Bronchial Cancer

NCT07085429 | Not Yet Recruiting

• 1 other identifier: PROICM 2021-11 BPO
• Study Type: interventional
• Target: 750
• Locations: 1 country
• Sites: 1

Brief Summary

A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments. This database is specific to bronchial cancer.

Conditions

Lung Cancer; Bronchial Cancer

Outcome Measures

Primary Outcomes (1)

• Proportion of patients who consent to participate in the study

  the proportion of patients who consent to participate in the study among the screened patients

  through study completion : an average of 1 year

Study Arms (1)

Bronchial cancer

EXPERIMENTAL

Additionnal samples from routine care of different natures (blood, tumor tissue ans healthy tissue) and standardized clinical data will be entered into a database.

Biological: Blood and tissue sampling

Interventions

Blood and tissue sampling BIOLOGICAL

Tissue samples (tumor tissue and healthy tissue) frozen and secured in paraffin collected during surgery. During the blood samples taken for diagnosis and / or treatment when possible. Additional samples for research purposes will be carried out, these blood samples will be collected: * before any therapeutic intervention (T1) for a total volume of 36mL, * prior to surgery (T-Surg) for a total volume of 24mL, * at each progression (T2a, b, c…) for a total volume of 24mL, * at the end of follow-up (T3) for a total volume of 24mL.

Bronchial cancer

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female patient aged over 18 years,
• Histologically or cytologically confirmed bronchial cancer,
• Treatment-naïve patient for the current cancer,
• Patient who has provided informed, written, and explicit consent,
• Patient affiliated with the French national health insurance system.

You may not qualify if:

• Patient with a WHO performance status ≥ 3,
• Pregnant and/or breastfeeding woman,
• Patient for whom regular follow-up is considered impossible due to psychological, familial, social, or geographic reasons,
• Patient under legal protection (guardianship, curatorship, or judicial protection).

Sponsors & Collaborators

• Institut du Cancer de Montpellier - Val d'Aurelle: lead

Study Sites (1)

Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle

Montpellier, France, 34298, France

Location

MeSH Terms

Conditions

Lung Neoplasms; Carcinoma, Bronchogenic

Interventions

Blood Specimen Collection

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases; Bronchial Neoplasms

Intervention Hierarchy (Ancestors)

Specimen Handling; Clinical Laboratory Techniques; Diagnostic Techniques and Procedures; Diagnosis; Punctures; Surgical Procedures, Operative; Investigative Techniques

Central Study Contacts

Emmanuelle TEXIER

CONTACT

467613102; emmanuelle.texier@icm.unicancer.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 2, 2025
• First Posted: July 25, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): September 1, 2030
• Study Completion (Estimated): September 1, 2040
• Last Updated: July 25, 2025

Record last verified: 2025-07

Locations

FR (1)